Abstract
ATP-binding cassette (ABC) transporters are highly expressed by brain endothelial cells that form the blood–brain barrier (BBB). These efflux pumps play an important role in maintaining brain homeostasis as they actively hinder the entry of unwanted blood-derived compounds into the central nervous system (CNS). Consequently, their high activity at the BBB has been a major hurdle for the treatment of several brain diseases, as they prevent numerous drugs to reach their site of action within the brain. Importantly, recent data indicate that endogenous substrates for ABC transporters may include inflammatory mediators, such as prostaglandins, leukotrienes, cytokines, chemokines, and bioactive lipids, suggesting a potential role for ABC transporters in immunological responses, and more specifically in inflammatory brain disorders, such as multiple sclerosis (MS). In this review, we will give a comprehensive overview of recent findings that illustrate this novel role for ABC transporters in neuro-inflammatory processes. Moreover, we will provide first insights into underlying mechanisms and focus on the importance for bioactive lipids, in particular platelet-activating factor, herein. A thorough understanding of these events may form the basis for the development for selective treatment modalities to dampen the neuro-inflammatory attack in MS and thereby reducing tissue damage.
ABC Transporters at the Blood–Brain Barrier
The blood–brain barrier (BBB) protects the central nervous system (CNS) from the entry of unwanted compounds and leukocytes, thereby maintaining brain homeostasis. However, during neuro-inflammatory diseases like multiple sclerosis (MS), immune cells traverse the endothelial barrier and accumulate within the brain parenchyma where they cause extensive tissue damage leading to neurological deficits (Frohman et al., 2006; Comabella and Khoury, 2012). The BBB is in essence formed by specialized brain endothelial cells, however surrounding cells, like astrocytes and pericytes also play a key role in maintenance of barrier features (Abbott et al., 2006). Next to the presence of complex tight junctions, barrier properties of the BBB are instated by the presence of specific endothelial ATP-binding cassette (ABC) transporters, which actively remove unwanted compounds from the brain. The ABC transporter family consists of a variety of efflux pumps (Loscher and Potschka, 2005a), of which a few are generally regarded as key BBB transporters, including P-glycoprotein (P-gp), breast-cancer resistance protein (BCRP), and the multi-drug resistance-associated proteins-1 and -2 (MRP-1, -2). In general, ABC transporters drive cellular exclusion of a variety of exogenous compounds and drugs through the cell membrane against a concentration gradient at the cost of ATP hydrolysis (Loscher and Potschka, 2005b). Expression and function of these transporters can be regulated by a broad variety of endogenous and exogenous factors, including nuclear receptors like steroid and xenobiotic receptors (Loscher and Potschka, 2005b) or a variety of inflammatory molecules (see review Miller, 2010).
ABC Transporters and Neuro-Inflammation
Most data on the function of ABC transporters originates from oncology research and is based on their capacity to cause multi-drug resistance (MDR; Lage, 2008). To date, evidence is accumulating that ABC transporters may also contribute to immunological processes based on their expression on various immune cells like antigen presenting cells (Randolph et al., 1998; van de Ven et al., 2006) and their potential to secrete inflammatory molecules like leukotrienes and prostaglandins (see review van de Ven et al., 2009). Together with their high expression on the BBB, ABC transporters may modulate inflammatory processes that occur in CNS disorders, including MS, a chronic inflammatory disorder of the CNS leading to severe neurological deficits. Pathologically, active MS lesions contain abundant cellular infiltrates, which mainly consist of T-cells and macrophages with a foamy appearance (Bruck et al., 1996). The latter acquire their distinctive morphology by ingestion and accumulation of vast amounts of myelin-derived lipids and cellular debris. Foamy macrophages originate from both resident microglia and infiltrating monocytes (Li et al., 1996) and are thought to contribute to myelin sheaths damage, resulting in neuronal dysfunction. In the course of lesion progression, enlarged proliferative astrocytes become the most predominant cell type. These reactive astrocytes secrete neurotrophic factors for neuronal survival, but also contribute to pathology by producing pro-inflammatory cytokines and chemokines (Tani et al., 1996; Speth et al., 2005; Sofroniew, 2009), which subsequently attract leukocytes into MS lesions.
ATP-binding cassette transporters have been implicated in various neurological disorders, including Alzheimer’s disease (Vogelgesang et al., 2002), HIV encephalitis (Langford et al., 2004), Parkinson’s disease (Bartels et al., 2008), and epilepsy (Sisodiya et al., 2002; Aronica et al., 2011). However, as these disorders lack a profound inflammatory component, the potential involvement for ABC transporters in neuro-inflammation has been long overseen. Conversely, we recently identified an important role for ABC transporters in neuro-inflammatory processes underlying MS pathogenesis (Kooij et al., 2009, 2010, 2011). We demonstrated that P-gp, MRP-1, and -2 are absent on healthy brain astrocytes, but their expression is highly increased on reactive astrocytes in MS lesions. In contrast, the expression of P-gp on endothelial cells of the BBB was slightly reduced in active lesions (Kooij et al., 2010), whereas the expression of endothelial BCRP, MRP-1 and -2 remained unaffected. Moreover, we showed that the astrocytic ABC transporters P-gp and MRP-1 mediated the secretion of chemokine (C–C motif) ligand 2 (CCL2), which in turn promotes immune cell migration in an in vitro model of the BBB (Kooij et al., 2011). In vivo evidence supporting a role for P-gp in immunomodulation was obtained using animals that lack P-gp (mdr1a/1b−/− animals), as they experience a significant reduction in clinical symptoms of experimental autoimmune encephalomyelitis (EAE; Kooij et al., 2009), a validated animal model for MS. Overall, these results strengthen the hypothesis that in addition to exporting unwanted compounds from cells, ABC transporters can actively interfere in immune processes by secreting inflammatory molecules, thereby illustrating a novel (patho)physiological role for these transporters in neuro-inflammatory disorders.
Bioactive Lipids
A controversial issue remains whether ABC transporters themselves are capable to transport inflammatory molecules as suggested by some groups (Gsur et al., 1996; Frank et al., 2001) or that ABC transporters mediate the secretion of other relevant physiological substrates, such as bioactive lipids (Raggers et al., 2001) that in turn affect cytokine secretion as a secondary effect (Huang et al., 1999). The latter seems plausible as a large group of ABC transporter substrates have a lipophilic nature (Lagas et al., 2008). To date, the ABC transporter mediated secretome of endogenous molecules remains to be determined, but likely include various bioactive lipids, which are known to regulate a variety of cellular signaling events through biophysical interactions with proteins that modify location, scaffolding, and signal transduction (Wiegmann et al., 1994; Ballou et al., 1996; Bradshaw et al., 1996; dam-Klages et al., 1998; Kronke, 1999). For example, rapid and transient alterations in the ceramide content of neuronal membranes have been shown to regulate neuronal excitability, synaptic transmitter release, plasma membrane insertion, and removal of transmembrane receptors (Inokuchi et al., 1997; Rohrbough et al., 2004; Kajimoto et al., 2007; Wheeler et al., 2009; Norman et al., 2010). Similarly, ceramide metabolism has been shown to direct immune activation through regulating the formation and function of the immunological synapse, T-cell activation, and cell death (Ballou et al., 1996; D’Souza et al., 1996; Solomon et al., 2003; Falcone et al., 2004; Detre et al., 2006). Other lipids such as sphingosine-1-phosphate, prostaglandins, arachidonic acid, and platelet-activating factor (PAF) act directly as second messengers. Many of these lipid metabolites are released from cells and act as ligands to regulate function through specific receptor interactions. Although many of these lipid metabolites are released from cells in a regulated manner, the exact underlying mechanisms are currently not well defined. Understanding how these lipid-derived second messengers are exported from cells will further increase our understanding of immune regulation and could identify specific therapeutic targets to dampen aberrant immune function in disease settings such as MS.
Mechanism of Action: Platelet-Activating Factor
Although the etiology of MS remains elusive, a crucial role has been established for the immune system, including a broad repertoire of inflammatory agents (Steinman, 2001; Hohlfeld and Wekerle, 2004; Comabella and Khoury, 2012). One of these agents is PAF, a potent pro-inflammatory phospholipid mediator with a wide range of biological activities (Stafforini et al., 2003). Several lines of evidence suggest a potential role for PAF in MS and EAE pathogenesis (Desai and Barton, 1990; Pedotti et al., 2003). Bioactivities of PAF are elicited by binding to the PAF receptor (PAFR), which belongs to the family of G-protein-coupled receptors (Honda et al., 1991). Interestingly, animals that lack the PAFR displayed lower incidence of disease and less severe clinical symptoms in the chronic phase of EAE compared to control mice (Kihara et al., 2005). Strikingly, no differences were observed in peripheral immune parameters that are associated with EAE, highlighting an important role for the PAFR in the neuropathology of EAE. Importantly, it has been demonstrated that PAF levels are elevated in the cerebrospinal fluid and plasma of MS patients (Callea et al., 1999). Together, these findings suggest that PAF likely contributes to MS pathogenesis; however, its cellular source in the CNS is yet unknown and data on the expression of PAFR in MS brain tissue remains elusive.
To first gain insight into the PAFR expression profile we performed a comprehensive immunohistochemical analysis to examine the distribution pattern of PAFR in various MS lesion stages. Classification of MS lesions was based on standard immunohistochemical analysis for myelin (proteolipid protein, PLP, Figure 1A). Active demyelination was demonstrated by the presence of phagocytic perivascular and parenchymal macrophages containing myelin degradation products (Figure 1A, insert) as described previously (van der Valk and De Groot, 2000; van Horssen et al., 2006a,b). In white matter from non-neurological control brain tissue (data not shown) and normal appearing white matter (NAWM) PAFR (Figure 1B) immunoreactivity was mainly restricted to glial cells (arrowheads). In active demyelinating lesions (Figure 1C) abundant PAFR staining was observed in foamy macrophages (arrows) and hypertrophic astrocytes (arrowhead), whereas endothelial cells only weakly express PAFR. In chronic inactive MS lesions, PAFR was consistently upregulated in reactive astrocytes (data not shown). Using double immunofluorescence analysis we confirmed the cellular localization of PAFR in active MS lesions and showed that it is expressed by CD86-positive macrophages (Figure 1D) and GFAP-positive astrocytes (Figure 1E). These results are in line with microarray data showing increased levels of PAFR transcripts in MS lesions (Lock et al., 2002), but illustrate for the first time the cellular origin of PAFR. Kihara and co-workers (Kihara et al., 2005) have shown that binding of PAF to its receptor increases the phagocytic activity of macrophages, a process that may likely occur in MS lesion development. However, the cellular source of PAF in the CNS during neuro-inflammation is to date unknown.
Figure 1
In general, PAF is produced by a variety of cells, including neutrophils, eosinophils, monocytes, macrophages, and vascular endothelial cells (Montrucchio et al., 2000). Although it is currently unknown how PAF is secreted from these cells, an important role has been suggested for ABC transporters like P-gp (Raggers et al., 2001). Our findings suggest an important role for P-gp on reactive astrocytes, as P-gp expression and function are highly increased early in the course of MS lesion formation (Kooij et al., 2011). Astrocytic P-gp may mediate the release of leukocyte attracting chemokines, a process that might be mediated by PAF. We isolated human primary reactive astrocytes directly from active MS lesions (as described previously by De Groot et al., 1997; Elkord et al., 2005) and cultured them in the presence or absence of the specific P-gp inhibitor reversin 121 for 6 h. Supernatants and cell pellets were harvested and PAF C16:0 levels were determined using liquid chromatography electro spray ionization mass spectrometry (LC/ESI/MS/MS; Wheeler et al., 2008). Notably, PAF secretion was significantly reduced in the presence of P-gp inhibition, whereas intracellular levels were increased (Figures 1F,G). These data strongly suggest a direct role for P-gp in the release of PAF form reactive astrocytes, and provide the first mechanistic insights in the role of bioactive lipids and ABC transporters in MS lesion formation.
Future Perspectives
Over the last decade, a novel role for ABC transporters in regulating immune responses is emerging. These new findings are challenging the current view of ABC transporters as gatekeepers of the BBB, but instead indicate that these transporters are able to contribute to degenerative and inflammatory responses under pathological conditions (Figure 2, model). Hence, further research is warranted to gain insight into the ABC transporter secretome under normal and inflammatory conditions to define a set of bioactive lipids that regulate the release of inflammatory mediators from cells. Moreover, future experiments need to define the exact mechanisms by which bioactive lipids induce cytokine/chemokine release from cells, or if they act as chemoattractants themselves (i.e., G-protein-coupled PAFR has many similarities with chemokine receptors). From a therapeutical point of view, targeting cell-specific ABC transporter substrates may be an attractive approach to dampen inflammation, as systemic inhibition of ABC transporters will likely cause major side effects. Next to that, more research is warranted to delineate the contribution of bioactive lipids in immune responses and neuro-inflammatory diseases like MS, using specific knock-out animals and/or selective inhibitors. Ultimately, this will open new therapeutic avenues to limit the neuro-inflammatory attack and prevent brain tissue damage.
Figure 2
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abbreviations
ABC, ATP-binding cassette; BBB, blood–brain barrier; BCRP, breast-cancer resistance protein; CCL2: chemokine (C–C motif) ligand 2; CNS, central nervous system; EAE, experimental autoimmune encephalomyelitis; MDR, multi-drug resistance; MRP, multi-drug resistance-associated protein; MS, multiple sclerosis; PAF, platelet-activating factor; PAFR, platelet-activating factor receptor; P-gp, P-glycoprotein.
References
1
AbbottN. J.RonnbackL.HanssonE. (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci.7, 41–53.10.1038/nrn1824
2
AronicaE.SisodiyaS. M.GorterJ. A. (2011). Cerebral expression of drug transporters in epilepsy. Adv. Drug Deliv. Rev. (in press).10.1016/j.addr.2011.11.008
3
BallouL. R.LaulederkindS. J.RosloniecE. F.RaghowR. (1996). Ceramide signalling and the immune response. Biochim. Biophys. Acta1301, 273–287.
4
BartelsA. L.WillemsenA. T.KortekaasR.de JongB. M.de VriesR.de KlerkO.van OostromJ. C.PortmanA.LeendersK. L. (2008). Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA. J. Neural Transm.115, 1001–1009.10.1007/s00702-008-0030-y
5
BradshawC. D.EllaK. M.ThomasA. L.QiC.MeierK. E. (1996). Effects of Ara-C on neutral sphingomyelinase and mitogen- and stress-activated protein kinases in T-lymphocyte cell lines. Biochem. Mol. Biol. Int.40, 709–719.
6
BruckW.SommermeierN.BergmannM.ZettlU.GoebelH. H.KretzschmarH. A.LassmannH. (1996). Macrophages in multiple sclerosis. Immunobiology195, 588–600.10.1016/S0171-2985(96)80024-6
7
CalleaL.AreseM.OrlandiniA.BargnaniC.PrioriA.BussolinoF. (1999). Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol.94, 212–221.10.1016/S0165-5728(98)00246-X
8
ComabellaM.KhouryS. J. (2012). Immunopathogenesis of multiple sclerosis. Clin. Immunol.142, 2–8.10.1016/j.clim.2011.11.008
9
dam-KlagesS.SchwandnerR.AdamD.KrederD.BernardoK.KrönkeM. (1998). Distinct adapter proteins mediate acid versus neutral sphingomyelinase activation through the p55 receptor for tumor necrosis factor. J. Leukoc. Biol.63, 678–682.
10
De GrootC. J.LangeveldC. H.JongenelenC. A.MontagneL.Van Der ValkP.DijkstraC. D. (1997). Establishment of human adult astrocyte cultures derived from postmortem multiple sclerosis and control brain and spinal cord regions: immunophenotypical and functional characterization. J. Neurosci. Res.49, 342–354.10.1002/(SICI)1097-4547(19970801)49:3<342::AID-JNR9>3.0.CO;2-C
11
DesaiS.BartonR. (1990). Role of platelet activating factor in the pathogenesis of active and passive models of experimental allergic encephalomyelitis in the rat. Agents Actions31, 43–46.10.1007/BF02003220
12
DetreC.KissE.VargaZ.LudányiK.PásztyK.EnyediA.KövesdiD.PanyiG.RajnavölgyiE.MatkóJ. (2006). Death or survival: membrane ceramide controls the fate and activation of antigen-specific T-cells depending on signal strength and duration. Cell. Signal.18, 294–306.10.1016/j.cellsig.2005.05.012
13
D’SouzaS. D.BonettiB.BalasingamV.CashmanN. R.BarkerP. A.TrouttA. B.RaineC. S.AntelJ. P. (1996). Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med.184, 2361–2370.10.1084/jem.184.6.2361
14
ElkordE.WilliamsP. E.KynastonH.RowbottomA. W. (2005). Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology114, 204–212.10.1111/j.1365-2567.2004.02076.x
15
FalconeS.PerrottaC.De PalmaC.PiscontiA.ScioratiC.CapobiancoA.Rovere-QueriniP.ManfrediA. A.ClementiE. (2004). Activation of acid sphingomyelinase and its inhibition by the nitric oxide/cyclic guanosine 3′,5′-monophosphate pathway: key events in Escherichia coli – elicited apoptosis of dendritic cells. J. Immunol.173, 4452–4463.
16
FrankM. H.DentonM. D.AlexanderS. I.KhouryS. J.SayeghM. H.BriscoeD. M. (2001). Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J. Immunol.166, 2451–2459.
17
FrohmanE. M.RackeM. K.RaineC. S. (2006). Multiple sclerosis–the plaque and its pathogenesis. N. Engl. J. Med.354, 942–955.10.1056/NEJMra052130
18
GsurA.HamiltonG.ZhaoS.AngerlerJ.FieglM.ZojerN.RadererM.HaberlI.AndreeffM.HuberH. (1996). Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood88, 1747–1754.
19
HohlfeldR.WekerleH. (2004). Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U.S.A.101(Suppl. 2), 14599–14606.10.1073/pnas.0404874101
20
HondaZ.NakamuraM.MikiI.MinamiM.WatanabeT.SeyamaY.OkadoH.TohH.ItoK.MiyamotoT.ShimizuT. (1991). Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature349, 342–346.10.1038/349342a0
21
HuangY. H.Schafer-ElinderL.WuR.ClaessonH. E.FrostegardJ. (1999). Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin. Exp. Immunol.116, 326–331.10.1046/j.1365-2249.1999.00919.x
22
InokuchiJ.MizutaniA.JimboM.UsukiS.YamagishiK.MochizukiH.MuramotoK.KobayashiK.KurodaY.IwasakiK.OhgamiY.FujiwaraM. (1997). Up-regulation of ganglioside biosynthesis, functional synapse formation, and memory retention by a synthetic ceramide analog (L-PDMP). Biochem. Biophys. Res. Commun.237, 595–600.10.1006/bbrc.1997.7194
23
KajimotoT.OkadaT.YuH.GoparajuS. K.JahangeerS.NakamuraS. (2007). Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons. Mol. Cell. Biol.27, 3429–3440.10.1128/MCB.01465-06
24
KiharaY.IshiiS.KitaY.TodaA.ShimadaA.ShimizuT. (2005). Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J. Exp. Med.202, 853–863.10.1084/jem.20050660
25
KooijG.MizeeM. R.van HorssenJ.ReijerkerkA.WitteM. E.DrexhageJ. A. R.van der PolS. M. A.van het HofB.SchefferG.ScheperR.DijkstraC. D.van der ValkP.de VriesH. E. (2011). Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain134, 555–570.10.1093/brain/awq330
26
KooijG.van HorssenJ.de LangeE. C.ReijerkerkA.van der PolS. M.van Het HofB.DrexhageJ.VennegoorA.KillesteinJ.SchefferG.OerlemansR.ScheperR.van der ValkP.DijkstraC. D.de VriesH. E. (2010). T lymphocytes impair P-glycoprotein function during neuroinflammation. J. Autoimmun.34, 416–425.10.1016/j.jaut.2009.10.006
27
KooijG.BackerR.KoningJ. J.ReijerkerkA.van HorssenJ.van der PolS. M. A.DrexhageJ.SchinkelA.DijkstraC. D.den HaanJ. M. M.GeijtenbeekT. B. H.de VriesH. E. (2009). P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS ONE4, e8212.10.1371/journal.pone.0008212
28
KronkeM. (1999). Biophysics of ceramide signaling: interaction with proteins and phase transition of membranes. Chem. Phys. Lipids101, 109–121.10.1016/S0009-3084(99)00059-6
29
LagasJ. S.SparidansR. W.van WaterschootR. A.WagenaarE.BeijnenJ. H.SchinkelA. H. (2008). P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin. Antimicrob. Agents Chemother.52, 1034–1039.10.1128/AAC.01041-07
30
LageH. (2008). An overview of cancer multidrug resistance: a still unsolved problem. Cell. Mol. Life Sci.65, 3145–3167.10.1007/s00018-008-8111-5
31
LangfordD.GrigorianA.HurfordR.AdameA.EllisR. J.HansenL.MasliahE. (2004). Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J. Neuropathol. Exp. Neurol.63, 1038–1047.
32
LiH.CuznerM. L.NewcombeJ. (1996). Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathol. Appl. Neurobiol.22, 207–215.10.1111/j.1365-2990.1996.tb00896.x
33
LockC.HermansG.PedottiR.BrendolanA.SchadtE.GarrenH.Langer-GouldA.StroberS.CannellaB.AllardJ.KlonowskiP.AustinA.LadN.KaminskiN.GalliS. J.OksenbergJ. R.RaineC. S.HellerR.SteinmanL. (2002). Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med.8, 500–508.10.1038/nm0502-500
34
LoscherW.PotschkaH. (2005a). Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx2, 86–98.10.1602/neurorx.2.1.86
35
LoscherW.PotschkaH. (2005b). Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci.6, 591–602.10.1038/nrn1728
36
MillerD. S. (2010). Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci.31, 246–254.10.1016/j.tips.2010.03.003
37
MontrucchioG.AlloattiG.CamussiG. (2000). Role of platelet-activating factor in cardiovascular pathophysiology. Physiol. Rev.80, 1669–1699.
38
NormanE.CutlerR. G.FlanneryR.WangY.MattsonM. P. (2010). Plasma membrane sphingomyelin hydrolysis increases hippocampal neuron excitability by sphingosine-1-phosphate mediated mechanisms. J. Neurochem.114, 430–439.10.1111/j.1471-4159.2010.06779.x
39
PedottiR.De VossJ. J.SteinmanL.GalliS. J. (2003). Involvement of both “allergic” and “autoimmune” mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol.24, 479–484.10.1016/S1471-4906(03)00233-3
40
RaggersR. J.VogelsI.vanM. G. (2001). Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem. J.357, 859–865.10.1042/0264-6021:3570859
41
RandolphG. J.BeaulieuS.PopeM.SugawaraI.HoffmanL.SteinmanR. M.MullerW. A. (1998). A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Natl. Acad. Sci. U.S.A.95, 6924–6929.10.1073/pnas.95.12.6924
42
RohrboughJ.RushtonE.PalankerL.WoodruffE.MatthiesH. J. G.AcharyaU.AcharyaJ. K.BroadieK. (2004). Ceramidase regulates synaptic vesicle exocytosis and trafficking. J. Neurosci.24, 7789–7803.10.1523/JNEUROSCI.1146-04.2004
43
SisodiyaS. M.LinW. R.HardingB. N.SquierM. V.ThomM. (2002). Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain125, 22–31.10.1093/brain/awf002
44
SofroniewM. V. (2009). Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci.32, 638–647.10.1016/j.tins.2009.08.002
45
SolomonJ. C.SharmaK.WeiL. X.FujitaT.ShiY. F. (2003). A novel role for sphingolipid intermediates in activation-induced cell death in T cells. Cell Death Differ.10, 193–202.10.1038/sj.cdd.4401136
46
SpethC.DierichM. P.SopperS. (2005). HIV-infection of the central nervous system: the tightrope walk of innate immunity. Mol. Immunol.42, 213–228.10.1016/j.molimm.2004.06.018
47
StafforiniD. M.McIntyreT. M.ZimmermanG. A.PrescottS. M. (2003). Platelet-activating factor, a pleiotropic mediator of physiological and pathological processes. Crit. Rev. Clin. Lab. Sci.40, 643–672.10.1080/714037693
48
SteinmanL. (2001). Multiple sclerosis: a two-stage disease. Nat. Immunol.2, 762–764.10.1038/ni0901-762
49
TaniM.GlabinskiA. R.TuohyV. K.StolerM. H.EstesM. L.RansohoffR. M. (1996). In situ hybridization analysis of glial fibrillary acidic protein mRNA reveals evidence of biphasic astrocyte activation during acute experimental autoimmune encephalomyelitis. Am. J. Pathol.148, 889–896.
50
van de VenR.de JongM. C.ReursA. W.SchoonderwoerdA. J.JansenG.HooijbergJ. H.SchefferG. L.de GruijlT. D.ScheperR. J. (2006). Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J. Immunol.176, 5191–5198.
51
van de VenR.OerlemansR.van der HeijdenJ. W.SchefferG. L.de GruijlT. D.JansenG.ScheperR. J. (2009). ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J. Leukoc. Biol.86, 1075–1087.10.1189/jlb.0309147
52
van der ValkP.De GrootC. J. (2000). Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol. Appl. Neurobiol.26, 2–10.10.1046/j.1365-2990.2000.00217.x
53
van HorssenJ.BoL.DijkstraC. D.de VriesH. E. (2006a). Extensive extracellular matrix depositions in active multiple sclerosis lesions. Neurobiol. Dis.24, 484–491.10.1016/j.nbd.2006.08.005
54
van HorssenJ.VosC. M.AdmiraalL.van HaastertE. S.MontagneL.van der ValkP.de VriesH. E. (2006b). Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol. Appl. Neurobiol.32, 585–593.10.1111/j.1365-2990.2006.00766.x
55
VogelgesangS.CascorbiI.SchroederE.PahnkeJ.KroemerH. K.SiegmundW.Kunert-KeilC.WalkerL. C.WarzokR. W. (2002). Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics12, 535–541.10.1097/00008571-200210000-00005
56
WheelerD.BandaruV. V.CalabresiP. A.NathA.HaugheyN. J. (2008). A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain131, 3092–3102.10.1093/brain/awn190
57
WheelerD.KnappE.BandaruV. V.WangY.KnorrD.PoirierC.MattsonM. P.GeigerJ. D.HaugheyN. J. (2009). Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J. Neurochem.109, 1237–1249.10.1111/j.1471-4159.2009.06038.x
58
WiegmannK.SchutzeS.MachleidtT.WitteD.KronkeM. (1994). Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell78, 1005–1015.10.1016/0092-8674(94)90275-5
Summary
Keywords
ATP-binding cassette transporters, blood–brain barrier, multiple sclerosis, astrocytes, bioactive lipids, platelet-activating factor, chemokines
Citation
Kooij G, van Horssen J, Bandaru VVR, Haughey NJ and de Vries HE (2012) The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids. Front. Pharmacol. 3:74. doi: 10.3389/fphar.2012.00074
Received
12 March 2012
Accepted
10 April 2012
Published
30 April 2012
Volume
3 - 2012
Edited by
Joana A. Palha, University of Minho, Portugal
Reviewed by
Muzamil Ahmad, Indian Institute of Integrative Medicine, India; Raja S. Settivari, The Dow Chemical Company, USA
Copyright
© 2012 Kooij, van Horssen, Bandaru, Haughey and de Vries.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
*Correspondence: Helga E. de Vries, Blood-Brain Barrier Research Group, Department of Molecular Cell Biology and Immunology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, Netherlands. e-mail: he.devries@vumc.nl
This article was submitted to Frontiers in Neuropharmacology, a specialty of Frontiers in Pharmacology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.